Essex Bio-Technology Limited, an investment holding company, develops, manufactures, and sells biologic drugs in China, Hong Kong, and internationally. It operates through Ophthalmology, Surgical, and Healthcare and Partner Services segments. The company researches and develops therapeutic fibroblast growth factor products to treat cellular proliferation, differentiation, and migration. It offers Beifushu series, such as Beifushu eye drops, eye gel, and unit-dose eye drops to treat ocular wounds; and Tobramycin, Levofloxacin, Sodium Hyaluronate, Diquafosol Sodium, and Moxifloxacin Hydrochloride eye drops, as well as Iodized lecithin capsules. The company also provides healthtech e-platform-related medical services, Beifuji spray and lyophilized powder, and Beifuxin gels to treat surface wounds. It offers Carisolv, a dental caries removal gel; mouthwash; oral care products; portable ultraviolet phototherapy devices; PELNACTM, a collagen-based artificial dermis; SCALGENTM, a double-layered artificial dermis; bioresorbable implants for dental surgery; hydrophilic contact lens; and other medical devices for myopia control and prevention; eye-protection lamp; and defocus customized glasses. The company develops SkQ1 eye drop, which is in the second phase 3 clinical trial; Bevacizumab ophthalmic injection for wet-AMD, which is in phase 3 clinical trial; and EB11-21148P, which is in phase 2 clinical trial, as well as new therapeutics in oncology, orthopedics, and neurology. It has license agreements with Mitotech S.A. for a clinical trial of an ophthalmic solution containing SkQ1 for dry eye disease; and Shanghai Henlius Biotech Inc. to co-develop a pharmaceutical product that contains an anti-vascular endothelial growth factor as a drug substance, which is intended to treat macular degeneration. The company was founded in 1990 and is headquartered in Zhuhai, China.